文献速递MDS 与骨髓增殖性肿瘤

估算脉搏波速度作为原发性血小板增多症和真性红细胞增多症主要不良心血管事件的标志物

Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera.
PubMed 文献 · Br J Haematol · 2026-09-08

本研究在664例原发性血小板增多症或真性红细胞增多症患者中评估基线估算脉搏波速度(ePWV)与主要不良心血管事件(MACE)及总生存(OS)的关联。中位随访67.4个月,58例发生首次MACE,58例死亡。多变量分析显示基线ePWV每升高1 m/s与MACE独立相关(HR 1.16,95%CI 1.02-1.32;p=0.025),但校正年龄后与OS无显著关联。

要点

  • 基线ePWV每升高1 m/s,MACE风险增加16%(HR 1.16,95%CI 1.02-1.32)
  • ePWV与动脉血栓风险边缘相关(HR 1.18,95%CI 1.00-1.39;p=0.054)
  • JAK2突变患者中V617F等位基因负荷与ePWV显著相关(ρ=0.134;p=0.022)

核心结论

  • ePWV是MPN患者中可扩展的血管老化标志物,与心血管风险相关,需前瞻性验证。

研究设计与样本

  • 纳入664例原发性血小板增多症(n=477)或真性红细胞增多症(n=187)患者,评估基线ePWV与MACE及OS的关联。

主要发现

  • 中位ePWV为11.1 m/s(IQR 9.2-12.9),72.1%符合早期血管老化标准(≥9.4 m/s)。
  • 中位随访67.4个月,发生58例首次MACE(8.7%)和58例死亡(8.7%)。
  • 多变量病因特异性Cox模型:基线ePWV每升高1 m/s与MACE独立相关(HR 1.16,95%CI 1.02-1.32;p=0.025)。
  • 动脉血栓调整后HR 1.18(95%CI 1.00-1.39;p=0.054),静脉血栓栓塞调整后HR 0.98(95%CI 0.74-1.28;p=0.860)。
  • 校正年龄后ePWV与OS无显著关联(HR 0.92,p=0.670)。

临床怎么用

  • ePWV或可作为MPN患者心血管风险分层的简易标志物,但尚需前瞻性研究验证。

局限性

  • 回顾性设计,ePWV与OS的关联在年龄校正后失去显著性,需前瞻性验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Estimated pulse wave velocity (ePWV), a simple surrogate of arterial stiffness, predicts cardiovascular events in general and oncology populations, but its relevance in myeloproliferative neoplasms (MPN) is unknown. We evaluated the association of baseline ePWV with major adverse cardiovascular events (MACE) and overall survival (OS) in 664 patients with essential thrombocythaemia (n = 477) or polycythaemia vera (n = 187). Median ePWV was 11.1 m/s (interquartile range [IQR], 9.2-12.9), and 72.1% met criteria for early vascular ageing (≥9.4 m/s). Over a median follow-up of 67.4 months, 58 first MACE (8.7%) and 58 deaths (8.7%) occurred. In multivariable cause-specific Cox models, each 1 m/s higher baseline ePWV was independently associated with MACE (hazard ratio [HR] 1.16, 95% confidence interval [CI] 1.02-1.32; p = 0.025). The adjusted HRs were 1.18 (95% CI 1.00-1.39; p = 0.054) for arterial thrombosis and 0.98 (95% CI 0.74-1.28; p = 0.860) for venous thromboembolism. For OS, ePWV lost significance after adjustment for age (HR 0.92, p = 0.670). Among JAK2-mutated patients, JAK2 V617F variant allele fraction showed a significant correlation with ePWV (ρ = 0.134; p = 0.022). These findings identify ePWV as a scalable marker of vascular ageing associated with cardiovascular risk in MPN, warranting prospective validation.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Costa A, Mulas O, Pilo F, et al. Estimated pulse wave velocity as a marker of major adverse cardiovascular events in essential thrombocythaemia and polycythaemia vera. Br J Haematol. 2026. PMID: 42708197. doi:10.1111/bjh.70820

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。